zolazepam

TELAZOL is indicated in dogs for restraint and minor procedures of short duration (30 min. avg.) requiring mild to moderate analgesia. Minor surgery is considered to be laceration repair, draining of abscesses, castrations and other procedures requiring mild to moderate analgesia.(See Dogs under Dosage and Administration.)TELAZOL administered intravenously is indicated in dogs for induction of anesthesia followed by maintenance with an inhalant anesthetic.

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Telazol®

Tzed™ is indicated in dogs for restraint and minor procedures of short duration (30 min. avg.) requiring mild to moderate analgesia.

Tzed™

For restraint and minor procedures of short duration (30 min. avg.) requiring mild to moderate analgesia.

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Not for use in dogs with pancreatic disease. Not for use in dogs with severe cardiac or pulmonary dysfunction. Not for use in pregnant bitches at any stage of pregnancy. Not for use for Cesarean sections. The dosage should be reduced in geriatric dogs, in animals in debilitated condition, and in animals with impairment of renal function.

ZOLETIL®

Indicated for induction of anesthesia followed by maintenance with an inhalant anesthetic.

ZOLETIL®

TELAZOL is indicated in cats for restraint or for anesthesia combined with muscle relaxation.

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Telazol®

For restraint or for anesthesia combined with muscle relaxation.

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Not for use in cats with pancreatic disease. Not for use in cats with severe cardiac or pulmonary dysfunction. Not for use in pregnant queens at any stage of pregnancy. Not for use for Cesarean sections. Not recommended for use in cats suffering from renal insufficiency. The dosage should be reduced in geriatric cats, in animals in debilitated condition, and in animals with impairment of renal function.

ZOLETIL®

Dogs TELAZOL is indicated in dogs for restraint and minor procedures of short duration (30 min. avg.) requiring mild to moderate analgesia. Minor surgery is considered to be laceration repair, draining of abscesses, castrations and other procedures requiring mild to moderate analgesia. (See Dogs under Dosage and Administration.) TELAZOL administered intravenously is indicated in dogs for induction of anesthesia followed by maintenance with an inhalant anesthetic. Cats TELAZOL is indicated in cats for restraint or for anesthesia combined with muscle relaxation.

Telazol® CIII(tiletamine and zolazepam for injection)

Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

Tzed™ CIII (tiletamine and zolazepam for injection)

Mechanism of Action ZOLETIL® (tiletamine and zolazepam for injection) is a rapid-acting anesthetic combination of tiletamine hydrochloride and zolazepam hydrochloride. Tiletamine hydrochloride is a dissociative anesthetic agent whose pharmacologic action is characterized by profound analgesia, normal pharyngeal-laryngeal reflexes and cataleptoid anesthesia. The anesthetic state produced does not fit into the conventional classification of stages of anesthesia, but instead ZOLETIL produces a state of unconsciousness which has been termed “dissociative’’ anesthesia in that it appears to selectively interrupt association pathways to the brain before producing somesthetic sensory blockade. Cranial nerve and spinal reflexes remain active; however, these reflexes must not be confused with inadequate anesthesia. Analgesia results from apparent selective interruption of sensory inputs to the brain and usually persists after the anesthetic effect has subsided. Protective reflexes, such as coughing and swallowing, are maintained under tiletamine anesthesia. Other reflexes, e.g., corneal, pedal, are maintained during tiletamine anesthesia, and should not be used as criteria for judging depth of anesthesia. The eyes normally remain open with the pupil dilated. It is suggested that a bland ophthalmic ointment be applied to the cornea if anesthesia is to be prolonged. Used alone, tiletamine hydrochloride does not provide adequate muscle relaxation for abdominal surgical procedures. When combined with zolazepam hydrochloride, good muscle relaxation is generally attained during the phase of deep surgical anesthesia. Pharmacokinetics The pharmacokinetics of tiletamine and zolazepam for injection, injectable solution was evaluated in 12 healthy adult Beagle dogs, following a single intravenous (IV) administration of 2.2 mg/kg bodyweight, which is equivalent to 1.1 mg/kg for both tiletamine hydrochloride and zolazepam hydrochloride. After administration of 2.2 mg/kg tiletamine and zolazepam for injection IV, the initial mean concentration of tiletamine (C 0 ) was 1018 ng/mL, the systemic clearance (CL) was 6223 mL/kg/h, the area under the curve to the last measured concentration (AUC 0-last ) was 178 ng*hr/mL, and steady state volume of distribution (V ss ) was 3250 mL/kg. The mean elimination half-life of tiletamine was 0.87 hours. For zolazepam, the mean C 0 was 2594 ng/mL, CL was 1993 mL/kg/h and V ss was 604 mL/kg. The mean elimination half-life of zolazepam was 0.41 hours. The mean C 0 and AUC 0-t(last) were approximately 2.5 and 3 times, respectively, greater for zolazepam than for tiletamine. However, the mean half-life (T 1/2 ) of tiletamine was approximately 2.5 times longer than for zolazepam, resulting in quantifiable plasma concentrations up to 2 hours longer. Pretreatment with an alpha2 -agonist or phenothiazine followed by inhalant isoflurane has been shown to increase in the initial concentration of both tiletamine and zolazepam.

ZOLETIL® (tiletamine and zolazepam for injection)

The use of TELAZOL is contraindicated in dogs and cats with pancreatic disease. TELAZOL is excreted predominantly by the kidneys. Preexistent renal pathology or impairment of renal function may be expected to result in prolonged duration of anesthesia. TELAZOL should not be used in dogs and cats with severe cardiac or pulmonary dysfunction. Because the teratogenic potential of TELAZOL is unknown, it should not be used in pregnant bitches or queens at any stage of pregnancy. Also, a study has shown that TELAZOL crosses the placental barrier and produces respiratory depression in the newborn; therefore, its use for Cesarean section is contraindicated.

Telazol® CIII(tiletamine and zolazepam for injection)

The use of ZOLETIL is contraindicated in dogs and cats with pancreatic disease. ZOLETIL should not be used in dogs and cats with severe cardiac or pulmonary dysfunction. Because the teratogenic potential of ZOLETIL is unknown, it should not be used in pregnant bitches or queens at any stage of pregnancy. Also, a study has shown that tiletamine and zolazepam for injection crosses the placental barrier and produces respiratory depression in the newborn; therefore, its use for Cesarean section is contraindicated.

ZOLETIL® (tiletamine and zolazepam for injection)

FOR USE IN DOGS AND CATS ONLY. When using ZOLETIL for induction of anesthesia, patients should be continuously monitored. Facilities for the maintenance of a patent airway, artificial ventilation and oxygen supplementation should be available. Pulmonary edema has been reported to occur in cats with the use of tiletamine and zolazepam for injection. Signs and symptoms include dyspnea, lethargy, anorexia and abnormal behavior. Deaths have been reported occasionally in severely affected individuals. Cats should be observed closely for any signs and symptoms which may suggest pulmonary edema so that appropriate therapy may be instituted. The principal route of excretion of both components in the cat is the urine; therefore, ZOLETIL is not recommended for use in cats suffering from renal insufficiency. Balance studies in dogs indicated extensive biotransformation of both components with less than 4% of the dose excreted unchanged in the urine. ZOLETIL is excreted predominantly by the kidneys. Preexistent renal pathology or impairment of renal function may be expected to result in prolonged duration of anesthesia. Phenothiazine-derivative drugs should not be used with ZOLETIL at dosages indicated for intramuscular (IM) injection because the combination produces respiratory and myocardial depression, hypotension and hypothermia. The safe use of ZOLETIL in pregnant animals or on reproduction has not been established. ZOLETIL crosses the placental barrier and causes respiratory depression in the neonate.

ZOLETIL® (tiletamine and zolazepam for injection)

FOR USE IN DOGS AND CATS ONLY. When using Tzed for induction of anesthesia, patients should be continuously monitored. Facilities for the maintenance of a patent airway, artificial ventilation and oxygen supplementation should be available. Pulmonary edema has been reported to occur in cats with the use of tiletamine and zolazepam for injection. Signs and symptoms include dyspnea, lethargy, anorexia and abnormal behavior. Deaths have been reported occasionally in severely affected individuals. Cats should be observed closely for any signs and symptoms which may suggest pulmonary edema so that appropriate therapy may be instituted. The principal route of excretion of both components in the cat is the urine; therefore, Tzed is not recommended for use in cats suffering from renal insufficiency. Balance studies in dogs indicated extensive biotransformation of both components with less than 4% of the dose excreted unchanged in the urine. Tzed is excreted predominantly by the kidneys. Preexistent renal pathology or impairment of renal function may be expected to result in prolonged duration of anesthesia. Phenothiazine-derivative drugs should not be used with Tzed at dosages indicated for intramuscular (IM) injection because the combination produces respiratory and myocardial depression, hypotension and hypothermia. The safe use of Tzed in pregnant animals or on reproduction has not been established. Tzed crosses the placental barrier and causes respiratory depression in the neonate.

Tzed™ CIII (tiletamine and zolazepam for injection)

FOR USE IN DOGS AND CATS ONLY. When using TELAZOL for induction of anesthesia, patients should be continuously monitored. Facilities for the maintenance of a patent airway, artificial ventilation and oxygen supplementation should be available. Pulmonary edema has been reported to occur in cats with the use of TELAZOL. Signs and symptoms include dyspnea, lethargy, anorexia and abnormal behavior. Deaths have been reported occasionally in severely affected individuals. Cats should be observed closely for any signs and symptoms which may suggest pulmonary edema so that appropriate therapy may be instituted. The principal route of excretion of both components in the cat is the urine; therefore, TELAZOL is not recommended for use in cats suffering from renal insufficiency. Balance studies in dogs indicated extensive biotransformation of both components with less than 4% of the dose excreted unchanged in the urine. TELAZOL is excreted predominantly by the kidneys. Preexistent renal pathology or impairment of renal function may be expected to result in prolonged duration of anesthesia. Phenothiazine-derivative drugs should not be used with TELAZOL at dosages indicated for intramuscular (IM) injection because the combination produces respiratory and myocardial depression, hypotension and hypothermia. The safe use of TELAZOL in pregnant animals or on reproduction has not been established. TELAZOL crosses the placental barrier and causes respiratory depression in the neonate.

Telazol® CIII(tiletamine and zolazepam for injection)

100 mg/mL total (equivalent to 50 mg/mL tiletamine and 50 mg/mL zolazepam) For Intramuscular and Intravenous Injection in Dogs For Intramuscular Injection only in Cats

ZOLETIL® (tiletamine and zolazepam for injection)

For Restraint and Minor Procedures of Short Duration Requiring Mild to Moderate Analgesia Respiratory depression may occur following administration of high doses of ZOLETIL. If at any time respiration becomes excessively depressed and the animal becomes cyanotic, resuscitative measures should be instituted promptly. Adequate pulmonary ventilation using either oxygen or room air is recommended as a resuscitative measure. Adverse reactions reported include emesis during emergence, excessive salivation, transient apnea, vocalization, erratic recovery and prolonged recovery, excessive tracheal and bronchial secretions when atropine sulfate, was not given before anesthesia, involuntary muscular twitching, hypertonicity, cyanosis, cardiac arrest, pulmonary edema and muscle rigidity during surgical procedures. Central nervous system stimulation and convulsions have also been reported. Tachycardia frequently occurs, particularly in the dog. This rise in heart rate usually lasts about 30 minutes. Either hypertension or hypotension may also occur. Insufficient anesthesia has been reported in dogs. Death has been reported in dogs and cats following tiletamine and zolazepam for injection administration. Intravenous Induction of Anesthesia followed by Maintenance with Inhalant Anesthesia in Dogs In a field study to assess the effectiveness and safety of tiletamine and zolazepam for injection administered intravenously at 1-2 mg/lb (2.2-4.4 mg/kg) for the induction of anesthesia followed by maintenance with inhalant anesthesia in dogs, 144 dogs were intravenously administered tiletamine and zolazepam for injection (See EFFECTIVENESS). Sixteen adverse reactions occurred during the study: nystagmus (5), emesis (4), diarrhea (2), and one occurrence each of hypersalivation, urticaria, anorexia, hyperthermia, and lethargy. All adverse reactions resolved by the end of the study. Physiologic abnormalities related to general anesthesia were transient and not severe. Post-induction apnea (time from induction to first inspiration ≥30 seconds) was observed in 49.3% of dogs across all treatment groups with a mean duration of one minute. The highest overall frequency and duration of post-induction apnea was in the alpha2-agonist + opioid groups. Overall, 36 dogs received assisted ventilation. Assisted ventilation was needed most frequently early in the procedure (at procedure start, possibly after an apneic period) then decreased in frequency as the procedure continued. Sixteen dogs experienced oxygen saturation (SpO2) ≤90 mmHg: 7 in the alpha2 -agonist + opioid groups, 6 in the phenothiazine +opioid groups, and 3 in the opioid alone groups. Twenty-five dogs had a temperature ≥103°F during the study, with 12 of these occurring prior to preanesthetic administration only. Of the remaining 13 dogs, 7 were in the alpha2-agonist + opioid groups, 5 were in the opioid alone groups, and 1 in the phenothiazine + opioid groups. One dog was reported with hyperthermia as an adverse reaction in the alpha2 -agonist + opioid treatment groups. The dog became excitable during recovery and its temperature elevated to 105.7°F. Hyperthermia resolved with treatment of IV fluids and cooling. Twenty-seven dogs experienced temperatures ≤96°F at one or more timepoints. Most dogs received supplemental heat during surgery. Fifty-nine dogs had mean blood pressure (BP) values ≤60 mmHg. These values are spread among all treatment groups. No dogs were reported with adverse reactions due to hypotension or hypertension in any dose groups. Elevated or low BP values were transient. Ventricular premature depolarizations were noted in 3 dogs in the alpha2-agonist + opioid group. This transient rhythm disturbance is not uncommon in dogs receiving alpha2 -agonists or inhalant anesthetics. One dog in the phenothiazine + opioid group showed transient ST depression that could have been due to cardiac hypoxia. All dogs recovered normally. To report suspected adverse drug events or for technical assistance contact Virbac AH, Inc. at 1-800-338-3659. Visit vet-us.virbac.com for product details. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at www.fda.gov/reportanimalae.

ZOLETIL® (tiletamine and zolazepam for injection)

DogsIntramuscular (IM) For Restraint and MinorProcedures of Short Duration Requiring Mild toModerate Analgesia:In healthy dogs, an initial intramuscular dosage of 3 to 4.5 mg/lb (6.6 to 9.9 mg/kg) TELAZOL is recommended for diagnostic purposes; 4.5 to 6 mg/lb (9.9 to 13.2 mg/kg) for minor procedures of short duration, such as treatment of lacerations and wounds, castrations and other procedures requiring mild to moderate analgesia. When supplemental doses of TELAZOL are required, such individual supplemental doses should be less than the initial dose, and the total dose given (initial dose plus supplemental dose or doses) should not exceed 12 mg/lb (26.4 mg/kg). The maximum safe dose is 13.6 mg/lb (29.92 mg/kg). (See Animal Safety.) Results from TELAZOL anesthesia in dogs will be more satisfactory if theprocedures are completed within one hour and if the procedures can be completed following single dose administration. In order to maintain at least a 2X margin of safety in dogs, the use of this product is limited to procedures that call for low doses (see Indications). Studies show that there is variation in response to different dosages of TELAZOL and that low doses do not give adequate levels of anesthesia, and in some instances do not give adequate analgesia, for extensive procedures.Intravenous (IV) For Induction of Anesthesia Followed by Maintenance with an Inhalant Anesthetic:In dogs, for induction of anesthesia, administer TELAZOL intravenously at 1-2 mg/lb (2.2-4.4 mg/kg) body weight to effect. TELAZOL should be administered slowly, over 30-45 seconds; after approximately 30-60 seconds, the dog’s level of consciousness, muscle relaxation, and jaw tone should be assessed to determine the ability to intubate. If after waiting 60 seconds the dog’s level of anesthesia is not sufficient for successful intubation, additional TELAZOL may be administered; the total dose should not exceed 2 mg/lb (4.4 mg/kg) body weight.

Intravenous

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Telazol®

The addition of 5 mL of sterile water for injection results in each one mL containing 50 mg tiletamine and 50 mg zolazepam.an initial intramuscular dosage of 3 to 4.5 mg/lb (6.6 to 9.9 mg/kg) is recommended for diagnostic purposes; 4.5 to 6 mg/lb (9.9 to 13.2 mg/kg) for minor procedures of short duration, such as treatment of lacerations and wounds, castrations and other procedures requiring mild to moderate analgesia. When supplemental doses are required, such individual supplemental doses should be less than the initial dose, and the total dose given (initial dose plus supplemental dose or doses) should not exceed 12 mg/lb (26.4 mg/kg). The maximum safe dose is 13.6 mg/lb (29.92 mg/kg).

Intramuscular, Intravenous

Tzed™

Intravenous (IV) (dogs only) For Induction of Anesthesia Followed by Maintenance with an Inhalant Anesthetic: In dogs, for induction of anesthesia, administer at 1–2 mg/lb (2.2–4.4 mg/kg) body weight to effect. Should be administered slowly, over 30-45 seconds; after approximately 30-60 seconds, the dog’s level of consciousness, muscle relaxation, and jaw tone should be assessed to determine the ability to intubate. If after waiting 60 seconds the dog’s level of anesthesia is not sufficient for successful intubation, additional Zoletil for Injection may be administered; the total dose should not exceed 2 mg/lb (4.4 mg/kg) body weight.

Intramuscular, Intravenous

ZOLETIL®

In healthy dogs, an initial intramuscular dosage of 3 to 4.5 mg/lb (6.6 to 9.9mg/kg) is recommended for diagnostic purposes; 4.5 to 6 mg/lb (9.9 to 13.2mg/kg) for minor procedures of short duration, such as treatment of lacerations and wounds, castrations and other procedures requiring mild to moderate analgesia. When supplemental doses are required, such individual supplemental doses should be less than the initial dose, and the total dose given (initial dose plus supplemental dose or doses) should not exceed 12 mg/lb (26.4 mg/kg).The maximum safe dose is 13.6 mg/lb (29.92 mg/kg).

Intramuscular, Intravenous

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Not for use in dogs with pancreatic disease. Not for use in dogs with severe cardiac or pulmonary dysfunction. Not for use in pregnant bitches at any stage of pregnancy. Not for use for Cesarean sections. The dosage should be reduced in geriatric dogs, in animals in debilitated condition, and in animals with impairment of renal function.

ZOLETIL®

Administer Tzed intravenously at 1–2 mg/lb (2.2–4.4 mg/kg) body weight to effect. Tzed should be administered slowly, over 30-45 seconds; after approximately 30-60 seconds, the dog’s level of consciousness, muscle relaxation, and jaw tone should be assessed to determine the ability to intubate. If after waiting 60 seconds the dog’s level of anesthesia is not sufficient for successful intubation, additional Tzed may be administered; the total dose should not exceed 2 mg/lb (4.4 mg/kg) body weight.

Intramuscular, Intravenous

Tzed™

The addition of 5 mL of sterile water for injection results in each one mL containing 50 mg tiletamine and 50 mg zolazepam an initial dosage of 4.4 to 5.4 mg/lb (9.7 to 11.9mg/kg) is recommended for such procedures as dentistry, treatment of abscesses, foreign body removal and related types of surgery; 4.8 to 5.7 mg/lb (10.6 to 12.5 mg/kg) for minor procedures requiring mild to moderate analgesia, such as repair of lacerations, castrations and other procedures of short duration. Initial dosages of 6.5 to 7.2 mg/lb (14.3 to 15.8 mg/kg) are recommended for ovariohysterectomy and onychectomy. When supplemental doses are required, such individual supplemental doses should be given in increments that are less than the initial dose, and the total dose given (initial dose plus supplemental doses) should not exceed the maximum allowable safe dose of 32.7 mg/lb (72 mg/kg).

Intramuscular, Intravenous

Tzed™

In healthy cats, an initial TELAZOL dosage of 4.4 to 5.4 mg/lb (9.7 to 11.9 mg/kg) IM is recommended for such procedures as dentistry, treatment of abscesses, foreign body removal and related types of surgery; 4.8 to 5.7 mg/lb (10.6 to 12.5 mg/kg) for minor procedures requiring mild to moderate analgesia, such as repair of lacerations, castrations and other procedures of short duration. Initial dosages of 6.5 to 7.2 mg/lb (14.3 to 15.8 mg/kg) are recommended for ovario hysterectomy and onychectomy. When supplemental doses of TELAZOL are required, such individual supplemental doses should be given in increments that are less than the initial dose, and the total dose given (initial dose plus supplemental doses) should not exceed the maximum allowable safe dose of 32.7 mg/lb (72 mg/kg). (See Animal Safety.)

Intravenous

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Telazol®

The dose is determined by the total combined concentration of 100 mg/mL (see HOW SUPPLIED) Dogs Intramuscular (IM) For Restraint and Minor Procedures of Short Duration Requiring Mild to Moderate Analgesia: In healthy dogs, an initial intramuscular dosage of 3 to 4.5 mg/lb (6.6 to 9.9 mg/kg) ZOLETIL is recommended for diagnostic purposes; 4.5 to 6 mg/lb (9.9 to 13.2 mg/kg) for minor procedures of short duration, such as treatment of lacerations and wounds, castrations and other procedures requiring mild to moderate analgesia. When supplemental doses of ZOLETIL are required, such individual supplemental doses should be less than the initial dose, and the total dose given (initial dose plus supplemental dose or doses) should not exceed 12 mg/lb (26.4 mg/kg). The maximum safe dose is 13.6 mg/lb (29.92 mg/kg). (See ANIMAL SAFETY.) Results from ZOLETIL anesthesia in dogs will be more satisfactory if the procedures are completed within one hour and if the procedures can be completed following single dose administration. In order to maintain at least a 2X margin of safety in dogs, the use of this product is limited to procedures that call for low doses (see INDICATIONS). Studies show that there is variation in response to different dosages of tiletamine and zolazepam for injection and that low doses do not give adequate levels of anesthesia, and in some instances do not give adequate analgesia, for extensive procedures. Intravenous (IV) For Induction of Anesthesia Followed by Maintenance with an Inhalant Anesthetic: In dogs, for induction of anesthesia, administer ZOLETIL intravenously at 1-2 mg/lb (2.2-4.4 mg/kg) body weight to effect. ZOLETIL should be administered slowly, over 30-45 seconds; after approximately 30-60 seconds, the dog’s level of consciousness, muscle relaxation, and jaw tone should be assessed to determine the ability to intubate. If after waiting 60 seconds the dog’s level of anesthesia is not sufficient for successful intubation, additional ZOLETIL may be administered; the total dose should not exceed 2 mg/lb (4.4 mg/kg) body weight. Cats In healthy cats, an initial ZOLETIL dosage of 4.4 to 5.4 mg/lb (9.7 to 11.9 mg/kg) IM is recommended for such procedures as dentistry, treatment of abscesses, foreign body removal and related types of surgery; 4.8 to 5.7 mg/lb (10.6 to 12.5 mg/kg) for minor procedures requiring mild to moderate analgesia, such as repair of lacerations, castrations and other procedures of short duration. Initial dosages of 6.5 to 7.2 mg/lb (14.3 to 15.8 mg/kg) are recommended for ovariohysterectomy and onychectomy. When supplemental doses of ZOLETIL are required, such individual supplemental doses should be given in increments that are less than the initial dose, and the total dose given (initial dose plus supplemental doses) should not exceed the maximum allowable safe dose of 32.7 mg/lb (72 mg/kg). (See ANIMAL SAFETY.)

INTRAMUSCULAR, INTRAVENOUS

ZOLETIL® (tiletamine and zolazepam for injection)

Fasting prior to induction of general anesthesia with ZOLETIL is not essential; however, when preparing for elective surgery, it is advisable to withhold food for at least 12 hours prior to ZOLETIL administration. As with other injectable anesthetic agents, the individual response to ZOLETIL is somewhat varied, depending upon the dose, general physical condition and age of the patient, duration of the surgical procedure, and any preanesthetics used. Therefore, recommendations for dosage regimens cannot be fixed absolutely. Specific dosage requirements must be determined by evaluation of the health status and condition of the patient and of the procedure to be performed. Recovery varies with the age and physical condition of the animal and the dose of ZOLETIL administered. Recovery is extended with high dose or multiple injections, particularly in cats. Intramuscular injection in dogs and cats: There may be pain on injection. This is especially prevalent in cats. Following a single, deep intramuscular injection of ZOLETIL in cats and dogs, onset of anesthetic effect usually occurs within 5 to 12 minutes. Muscle relaxation is optimum for approximately the first 20 to 25 minutes after ZOLETIL is administered, and then diminishes. Repeated doses increase the duration of the effect of ZOLETIL but may not further diminish muscle tone. The quality of anesthesia with repeated doses varies because the ratio of the two components within the animal’s body changes with each injection. This is due to the difference in the rates of metabolism and elimination of the two components. The quality of anesthesia will be improved and more predictable if the entire dose is given as a single injection rather than in several doses. The best method of evaluating the depth of ZOLETIL anesthesia is to monitor the patient for deliberate conscious response to nociceptive stimuli. If adequate anesthesia is not produced by the recommended dosage regimen, supplemental anesthesia or another agent is indicated. This includes the use of barbiturates and volatile anesthetics. When used concurrently with ZOLETIL the dosage of these agents should be reduced.

INTRAMUSCULAR, INTRAVENOUS

ZOLETIL® (tiletamine and zolazepam for injection)

To each vial add 5 mL sterile water for injection, USP. Slight agitation will facilitate complete reconstitution. The resultant solution will contain 100 mg total ZOLETIL per one milliliter (50 mg tiletamine and 50 mg zolazepam per mL). Discard unused solution after 4 days when stored at room temperature or after 70 days when kept refrigerated. Only use clear solution. Color of solution may vary from colorless to light amber.

INTRAMUSCULAR, INTRAVENOUS

ZOLETIL® (tiletamine and zolazepam for injection)

The dose is determined by the total combined concentration of 100 mg/mL (see HOW SUPPLIED)

INTRAMUSCULAR

Telazol® CIII(tiletamine and zolazepam for injection)